Levi & Korsinsky Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (SRPT)
New York, NY – July 18, 2025 – Levi & Korsinsky, LLP, a nationally recognized law firm specializing in securities litigation, today announced the filing of a securities class action lawsuit against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of its executives. The lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all purchasers of Sarepta Therapeutics securities between May 11, 2023, and April 11, 2024, inclusive.
The class action complaint alleges that Sarepta Therapeutics, a biopharmaceutical company focused on the development and commercialization of genetic therapies for rare neuromuscular diseases, made materially false and misleading statements during the class period. Specifically, the lawsuit claims that the company misrepresented the potential efficacy and safety of its Duchenne muscular dystrophy (DMD) therapies and engaged in practices that artificially inflated the company’s stock price.
Investors are alleging that Sarepta failed to disclose critical information regarding the scientific and regulatory challenges associated with its drug development programs. As a result, shareholders who purchased Sarepta stock at inflated prices during the specified period may have suffered significant financial losses.
The filing of this class action lawsuit aims to recover damages for Sarepta shareholders who were allegedly misled by the company’s public statements. Levi & Korsinsky, LLP, with its extensive experience in prosecuting securities fraud cases, is committed to representing the interests of these investors and ensuring accountability.
Shareholders who purchased Sarepta Therapeutics securities during the class period and wish to learn more about their rights and how to participate in this action are encouraged to contact Levi & Korsinsky, LLP. Further information can be obtained by visiting the firm’s website or by contacting them directly via email or phone.
This news represents a significant development for Sarepta Therapeutics and its shareholders, highlighting the importance of transparency and accurate disclosure in the pharmaceutical industry. The legal proceedings are expected to unfold in the coming months as the case progresses through the court system.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
www.prnewswire.com published ‘Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc.(SRPT) Shareholders’ at 2025-07-18 12:45. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.